Mechanism-driven cancer and immunology work emphasized new targets. A study in Nature Communications reported that inhibiting EP300 can restore antibacterial function in scar-associated macrophages in acute-on-chronic liver failure models, improving outcomes in mice. In colorectal cancer biology, researchers described how blocking ST6GAL1 reverses a sugar-linkage switch on macrophages, re-arming tumor-fighting behavior and slowing tumor cell growth in lab studies. In parallel, a multi-omics spatial analysis mapped lung tumor evolution under EGFR targeted therapy pressure, linking microenvironment remodeling to resistance stages. Across these findings, the focus is on reprogramming immune function and validating tractable targets connected to therapy response rather than relying solely on tumor-centric endpoints.